3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
33
Colorectal Neoplasms
13
Neoplasms
11
Pain, Postoperative
10
Lung Neoplasms
9
Brain Neoplasms
8
Stomach Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Melanoma
6
Leukemia, Myeloid, Acute
5
Ovarian Neoplasms
4
Myoma
4
Lymphoma, Non-Hodgkin
4
Leiomyoma
4
Hemorrhage
4
Head and Neck Neoplasms
4
Glioblastoma
4
Colonic Neoplasms
4
Agnosia
4
Skin Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neurotoxicity Syndromes
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Myelodysplastic Syndromes
3
Multiple Endocrine Neoplasia Type 1
3
Interventions
Imatinib Mesylate
67
Sunitinib
27
nilotinib
14
regorafenib
13
ripretinib
10
avapritinib
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
Laparoscopy
4
CTLA-4 Antigen
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Bevacizumab
3
trametinib
2
tanespimycin
2
ponatinib
2
pembrolizumab
2
masitinib
2
famitinib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Stromal Tumors
×
Sodium Chloride
×
Clear all
NCT01265810
2017-11-13
COMTT
Impaqtt Foundation
Phase 3
Completed
64 enrolled